JP2016539087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539087A5 JP2016539087A5 JP2016521266A JP2016521266A JP2016539087A5 JP 2016539087 A5 JP2016539087 A5 JP 2016539087A5 JP 2016521266 A JP2016521266 A JP 2016521266A JP 2016521266 A JP2016521266 A JP 2016521266A JP 2016539087 A5 JP2016539087 A5 JP 2016539087A5
- Authority
- JP
- Japan
- Prior art keywords
- sap
- serum amyloid
- agonist
- myelofibrosis
- agonist according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888269P | 2013-10-08 | 2013-10-08 | |
| US61/888,269 | 2013-10-08 | ||
| US201461992807P | 2014-05-13 | 2014-05-13 | |
| US61/992,807 | 2014-05-13 | ||
| US201462004836P | 2014-05-29 | 2014-05-29 | |
| US201462004828P | 2014-05-29 | 2014-05-29 | |
| US62/004,828 | 2014-05-29 | ||
| US62/004,836 | 2014-05-29 | ||
| PCT/US2014/059699 WO2015054390A1 (en) | 2013-10-08 | 2014-10-08 | Methods for treating fibrotic cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019229263A Division JP7140739B2 (ja) | 2013-10-08 | 2019-12-19 | 線維性癌の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539087A JP2016539087A (ja) | 2016-12-15 |
| JP2016539087A5 true JP2016539087A5 (https=) | 2018-05-31 |
| JP6636914B2 JP6636914B2 (ja) | 2020-01-29 |
Family
ID=52813618
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521266A Active JP6636914B2 (ja) | 2013-10-08 | 2014-10-08 | 線維性癌の治療方法 |
| JP2019229263A Active JP7140739B2 (ja) | 2013-10-08 | 2019-12-19 | 線維性癌の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019229263A Active JP7140739B2 (ja) | 2013-10-08 | 2019-12-19 | 線維性癌の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11020451B2 (https=) |
| EP (2) | EP3718558A1 (https=) |
| JP (2) | JP6636914B2 (https=) |
| CN (2) | CN105792831A (https=) |
| AU (2) | AU2014331954B2 (https=) |
| CA (1) | CA2926418A1 (https=) |
| ES (1) | ES2784234T3 (https=) |
| PL (1) | PL3054959T3 (https=) |
| RU (2) | RU2718056C2 (https=) |
| WO (1) | WO2015054390A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105792831A (zh) | 2013-10-08 | 2016-07-20 | 普罗麦迪奥股份有限公司 | 用于治疗纤维化癌症的方法 |
| CA2983004A1 (en) * | 2015-04-15 | 2016-10-20 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| KR102066402B1 (ko) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물 |
| US10960006B2 (en) * | 2018-01-31 | 2021-03-30 | Twi Pharmaceuticals, Inc. | Topical formulations comprising tofacitinib |
| KR20200139721A (ko) * | 2018-03-28 | 2020-12-14 | 블레이드 테라퓨틱스, 인크. | 섬유성 질환을 치료하는 방법 |
| CN108715865B (zh) * | 2018-05-28 | 2021-09-21 | 福建师范大学 | 用于提高细胞转染效率的试剂组合物 |
| JP7695885B2 (ja) | 2019-02-12 | 2025-06-19 | アンブルックス，インコーポレイテッド | 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用 |
| WO2020219423A1 (en) * | 2019-04-25 | 2020-10-29 | Clear Creek Bio, Inc. | Combination therapies including inhibitors of dihydroorotate dehydrogenase |
| CN112107556A (zh) * | 2019-06-03 | 2020-12-22 | 北京大学 | 一种含砷纳米药物及其制备方法 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| JP7850665B2 (ja) * | 2020-01-28 | 2026-04-23 | ラジエル セラピューティクス エルティーディー． | 血管脂肪腫の処置のための組成物 |
| KR102725907B1 (ko) * | 2021-11-25 | 2024-11-04 | 성균관대학교산학협력단 | 파크리티닙을 이용한 항암제 내성 암 치료를 위한 병용 요법 |
| KR20260016906A (ko) * | 2023-03-17 | 2026-02-04 | 엠디엑스 메니지먼트 엘엘씨 | 요법의 유해효과를 개선하기 위한 조성물 및 방법 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| EP0786469B1 (en) | 1990-06-11 | 2006-03-01 | Gilead Sciences, Inc. | Methods of use of nucleic acid ligands |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| CA2301166A1 (en) | 1997-07-24 | 1999-02-04 | Yuan-Peng Zhang | Liposomal compositions for the delivery of nucleic acid catalysts |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US8946387B2 (en) * | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8012472B2 (en) | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
| US7763256B2 (en) | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
| CN1946417A (zh) | 2003-12-05 | 2007-04-11 | 阿德内克休斯治疗公司 | 2型血管内皮生长因子受体的抑制剂 |
| CN101166539B (zh) * | 2005-02-08 | 2012-01-04 | 得克萨斯大学体系董事会 | 用于治疗癌症的涉及mda-7的组合物和方法 |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| HUE030269T2 (en) * | 2006-06-26 | 2017-04-28 | Macrogenics Inc | FC RIIB-specific antibodies and methods for their use |
| CA2708004C (en) | 2006-12-04 | 2015-12-01 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| US8497243B2 (en) * | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| US9884899B2 (en) * | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| WO2009009034A2 (en) * | 2007-07-06 | 2009-01-15 | Promedior, Inc | Methods and compositions useful in the treatment of mucositis |
| CA2755047C (en) | 2009-03-11 | 2018-12-04 | Promedior, Inc. | Treatment methods for autoimmune disorders |
| PT2405928T (pt) | 2009-03-11 | 2017-02-07 | Promedior Inc | Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade |
| US20100266643A1 (en) | 2009-04-01 | 2010-10-21 | Willett W Scott | Pulmonary and nasal delivery of serum amyloid p |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| EP2987803B1 (en) | 2009-06-17 | 2018-08-29 | Promedior Inc. | Sap variants and their use |
| US20130195861A1 (en) | 2011-12-21 | 2013-08-01 | Promedior, Inc. | Serum amyloid p-antibody fusion proteins |
| JP2015069119A (ja) | 2013-09-30 | 2015-04-13 | パナソニック液晶ディスプレイ株式会社 | 表示装置 |
| CN105792831A (zh) | 2013-10-08 | 2016-07-20 | 普罗麦迪奥股份有限公司 | 用于治疗纤维化癌症的方法 |
| CA2983004A1 (en) | 2015-04-15 | 2016-10-20 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
-
2014
- 2014-10-08 CN CN201480062728.5A patent/CN105792831A/zh active Pending
- 2014-10-08 CA CA2926418A patent/CA2926418A1/en active Pending
- 2014-10-08 RU RU2016117775A patent/RU2718056C2/ru active
- 2014-10-08 PL PL14851638T patent/PL3054959T3/pl unknown
- 2014-10-08 WO PCT/US2014/059699 patent/WO2015054390A1/en not_active Ceased
- 2014-10-08 AU AU2014331954A patent/AU2014331954B2/en not_active Ceased
- 2014-10-08 US US15/027,759 patent/US11020451B2/en active Active
- 2014-10-08 EP EP20150541.9A patent/EP3718558A1/en not_active Withdrawn
- 2014-10-08 EP EP14851638.8A patent/EP3054959B1/en active Active
- 2014-10-08 JP JP2016521266A patent/JP6636914B2/ja active Active
- 2014-10-08 RU RU2020111934A patent/RU2020111934A/ru unknown
- 2014-10-08 CN CN202111292205.8A patent/CN114053395A/zh active Pending
- 2014-10-08 ES ES14851638T patent/ES2784234T3/es active Active
-
2019
- 2019-12-19 JP JP2019229263A patent/JP7140739B2/ja active Active
-
2020
- 2020-08-20 AU AU2020220139A patent/AU2020220139A1/en not_active Abandoned
-
2021
- 2021-04-27 US US17/241,654 patent/US20210322515A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539087A5 (https=) | ||
| RU2020111934A (ru) | Способы лечения фиброзного рака | |
| JP2018512164A5 (https=) | ||
| US20220054531A1 (en) | Treatment of acute myeloid leukemia with hypomethylating agents and 2-o, 3-o desulfated heparinoids | |
| IL278667B1 (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| EP3197493B1 (en) | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent | |
| US20220313642A1 (en) | Tyrosine derivatives and compositions comprising them | |
| WO2015195476A1 (en) | Treating myelomas | |
| JP2022153587A (ja) | チロシン誘導体及びそれらを含む組成物 | |
| CN111601609A (zh) | 与细胞毒性剂组合的细菌脂多糖的脂质体制剂及其在抗肿瘤疗法中的用途 | |
| WO2012031293A1 (en) | Compositions and methods for the treatment of cancer | |
| WO2017152039A1 (en) | Protection and delivery of multiple therapeutic proteins | |
| CN1402639A (zh) | 药用组合物 | |
| CN100409895C (zh) | 用于治疗白血病和淋巴瘤的阿普立定组合 | |
| US20150283237A1 (en) | Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer | |
| EP3934690A1 (en) | Drug delivery for combination of epigenetic modulation and immune checkpoint blockade | |
| CN1845746A (zh) | 单独包含去纤苷酸或与其它抗肿瘤剂联合的抗肿瘤制剂 | |
| US20230074885A1 (en) | Bortezomib-loaded nanoparticles | |
| JP6782932B2 (ja) | Ｎｐｒ−ａアゴニストの新規用途 | |
| JP2009292837A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| US12233087B2 (en) | Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions | |
| TW202011946A (zh) | 以bet抑制劑及蛋白酶體抑制劑之組合療法 | |
| JPWO2014050912A1 (ja) | 二酸化炭素を溶解した液状医薬とそれを用いる治療方法 | |
| JPWO2020247440A5 (https=) | ||
| HK40056547A (en) | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |